Effect of dehydroxymethylepoxyquinomicin on human osteoclastogenesis and production of matrix metalloprotease-9 by human osteoclasts

<p><b>Copyright information:</b></p><p>Taken from "NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor"</p><p>http://arthritis-research.com/content/9/5/R97</p><p>Arthritis Research & Therapy 2007;9(5):R97-R97.</p><p>Published online 25 Sep 2007</p><p>PMCID:PMC2212584.</p><p></p> Peripheral blood monocytes were incubated in 96-well plates with macrophage colony-stimulating factor (M-CSF), receptor activator of NF-κB ligand (RANKL), and the indicated concentrations of dehydroxymethylepoxyquinomicin (DHMEQ). At day 7, the total number of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNC) with three or more nuclei/well was counted. Representative data of three independent experiments are shown. *< 0.01, DHMEQ versus dimethyl sulfoxide (DMSO). Peripheral blood monocytes were incubated in 96-well plates with M-CSF and RANKL without DHMEQ. At day 7, the medium was replaced with fresh medium and the indicated concentrations of DHMEQ were added. The culture supernatant was collected at day 8, and the matrix metalloprotease-9 (MMP-9) concentration was measured by ELISA. Representative data of two independent experiments are shown. Data represent the mean ± standard error of the mean of triplicate wells, and were compared by Student's test. *< 0.05, DHMEQ versus DMSO